Genprex, Inc. has received a significant patent from the Canadian Intellectual Property Office, enhancing its position in cancer therapy development through Reqorsa® Gene Therapy.

Genprex, Inc. is set to present remarkable preclinical data on GPX-002, a groundbreaking gene therapy for diabetes, during the ASGCT Annual Meeting in New Orleans.

Genprex doses first subject in expansion part of lung cancer gene therapy trial  Yahoo Finance

Genprex doses first subject in expansion part of lung cancer gene therapy trial  Clinical Trials Arena

Genprex will present the Acclaim-3 clinical trial design for its Reqorsa® gene therapy targeting extensive stage small cell lung cancer at the ASCO Annual Meeting in 2025.

The grant adds Israel to patents already issued in the U.S., Europe, Japan and other markets, extending protection for its cancer combo.

Genprex's diabetes gene therapy demonstrates significant potential for transforming Type 2 diabetes treatment at the 2026 ASGCT Annual Meeting in Austin, Texas.

Genprex, Inc. presented new clinical data indicating that biomarkers can predict response to Reqorsa® gene therapy in lung cancer at the ASCO 2026.

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting  Star Local Media

Genprex (NASDAQ: GNPX) has signed a new Sponsored Research Agreement (SRA) with the University of Pittsburgh to study GPX-002, its gene therapy treatment for Type 1 (T1D) and Type 2 diabetes (T2D) in animal models. Previous preclinical data showed statistically significant improvements in insulin requirements, c-peptide levels, and glucose tolerance. GPX-002 uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct. In T1D, it transforms alpha cells into functional beta-like cells that produce insulin while potentially evading immune response. For T2D, the therapy aims to rejuvenate exhausted beta cells. The treatment can be administered in humans through routine endoscopy.

Click to view the official SEC document.

Genprex, Inc. will present its lead clinical oncology and preclinical diabetes programs at the H.C. Wainwright Global Investment Conference held in NYC.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Andelyn Biosciences is set to enhance manufacturing processes for Genprex's diabetes gene therapy, aiding in preclinical studies and clinical trials for innovative treatments.

Genprex has selected a leading US-based organization to scale up its diabetes gene therapy manufacturing, aiming for safer and effective treatments.

Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on...